Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Angela McDonald

Physician Assistant Thornton, CO Physician Assistant

NPI 1972735488 CMS profile 10740902

3240 E 104Th Ave, Thornton, CO 80233

Open in the dashboard

General payments

$8,046

406 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Angela McDonald of Thornton, CO is reported in the CMS Open Payments database as having received $8,046 across 406 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,444 117
2024 General $1,762 83
2023 General $1,542 77
2022 General $1,269 72
2021 General $1,030 57

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Angela McDonald
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Angela McDonald were reported at $2,444. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Angela McDonald Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,030 $132 $37–$438 $132
2022 $1,269 $155 $48–$522 $149
2023 $1,542 $167 $52–$557 $160
2024 $1,762 $178 $55–$600 $164
2025 $2,444 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Regeneron Healthcare Solutions, Inc. $1,381 78 payments
  2. AstraZeneca Pharmaceuticals LP $1,323 60 payments
  3. GlaxoSmithKline, LLC. $1,167 60 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $708 29 payments
  5. Genzyme Corporation $482 26 payments
  6. CSL Behring $296 16 payments
  7. Novartis Pharmaceuticals Corporation $258 14 payments
  8. kaleo, Inc. $217 10 payments
  9. Lilly USA, LLC $204 11 payments
  10. AbbVie, Inc. $195 11 payments
  11. Other $1,816 91 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,760 400 payments
  2. Education $212 4 payments
  3. Consulting Fee $73 2 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT Inflammation And Immunology $1,055 63 payments
  2. DUPIXENT Immunology $821 43 payments
  3. NUCALA $626 28 payments
  4. FASENRA $616 26 payments
  5. TRELEGY ELLIPTA $520 31 payments
  6. TEZSPIRE $489 20 payments
  7. BREZTRI $379 12 payments
  8. DUPIXENT Immunology And Inflammation $325 15 payments
  9. TAKHZYRO $282 11 payments
  10. GLASSIA $236 10 payments
  11. Other $3,435 177 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

321

Median for Physician Assistant: 241

Drug cost

$2,466,811

Median for Physician Assistant: $4,110

Branded share of claims

58.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ruconest C1 Esterase Inhibitor, Recomb Brand 20 $2,173,688
Privigen Immun Glob G(Igg)/Pro/Iga 0-50 Brand 17 $99,715
Xolair Omalizumab Brand 26 $94,572
Dupixent Syringe Dupilumab Brand 20 $77,890
Symbicort Budesonide/Formoterol Fumarate Brand 27 $8,109
Cromolyn Sodium Generic 17 $4,515
Qvar Redihaler Beclomethasone Dipropionate Brand 11 $3,265
Albuterol Sulfate Hfa Albuterol Sulfate Brand 27 $1,471
Ventolin Hfa Albuterol Sulfate Brand 24 $1,312
Synthroid Levothyroxine Sodium Brand 15 $1,018

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$666,601

Of which drugs: $637,250

Medicare patients

117

Average age 63

Services billed

10,033

89 women, 28 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 51%
High blood pressure 44%
Depression 32%
Osteoporosis 21%
Diabetes 18%
COPD 15%
Ischemic heart disease 14%
Chronic kidney disease 9%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg J1568 Office 16 4,670 $172,988

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $309
  • GENZYME CORPORATION $102
$412 20 —
NUCALA
  • GlaxoSmithKline, LLC. $143
$143 — —
FASENRA
  • AstraZeneca Pharmaceuticals LP $112
$112 — —
GLASSIA
  • Takeda Pharmaceuticals U.S.A., Inc. $107
$107 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $107
$107 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

406 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record